Hot Off the Press – Potential Treatment for CMT1A

by | Mar 9, 2015 | 53 comments

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

In preclinical studies, PXT-3003 was shown in vitro to synergistically increase myelination of axons cocultured with CMT1A rat Schwann cells. The combination of drugs was also shown to lower PMP22 expression (which at high levels in CMT1A is responsible for dysmyelination and consequently axonal loss and muscle atrophy). In the rat model of CMT1A different measures of effectiveness suggested that PXT-3003 was also promising and likely efficacious. The very low doses of all three components would also negate any adverse side effects.

The phase II clinical trial used three dose levels of PXT-3003 in 80 adults with mild to moderate CMT1A. The trial confirmed the safety of the combination drug and the best improvement was seen at the highest dose. PXT-3003 was safe and well tolerated. PXT-3003 showed, beyond stabilization, a significant improvement in the Overall Neuropathy Limitation Scale (ONLS) versus the placebo group. ONLS is a major scale to evaluate disability of upper and lower limbs for peripheral neuropathy. This represents the most promising potential treatment to date after ascorbic acid (vitamin C) failed to demonstrate efficacy for CMT1A in various clinical trials.

There are still gaps in understanding the mechanism of how PXT-3003 actually exerts its effect. It is hoped that by looking at patients over a longer period and possibly treating them earlier before the disease clinically affects them, this may improve nerve conduction and potentially halt and reverse disease. PXT-3003 represents a new hope for CMT1A patients in years, but there is still a long way to go (several years) before it may be more widely available as an FDA and EMA approved treatment for CMT1A.

An International Phase 3 trial will enroll later this year both in the US and Europe.

If you are interested in participating in the clinical trial, join the Global Registry for Inherited Neuropathies (GRIN).

 

Learn more on this topic

Related Blog Posts

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Dr. Robert Baloh Answers Our Questions About iPS Cell Research

Big news is happening on a cellular level at Cedars-Sinai Medical Center’s Regenerative Medicine Institute in Los Angeles, CA.  Robert H. Baloh, MD PhD, Director of Neuromuscular Medicine, in conjunction with Patrick D. Lyden, MD Neurology Dept. Chair, and Clive Svendsen, PhD, Institute Director, are studying disorders that start in nerve cells. 

Join the conversation

Leave a Comment

53 Comments

  1. Christopher Ball

    Will children or teens be eligible for the phase 3 trial? My 14 (15 by 05/29) year old daughter has CMT1a. Recent EMG / nerve conduction present as “severe”. We live in N. Georgia and currently travel to S.R. CHOA in Atlanta for Ortho and Neuro Dr’s.

    Reply
  2. Brady Smith

    Please sign me up for the newsletter. I have CMT and am interested in getting information. Thanks.

    Reply
    • courtney

      Thanks Brady! You are all signed up for our newsletters.

      Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news